Real-World Evidence: Sanofi Push Driven By Aetion Deal
Facilitating Regulatory-Grade Clinical Studies
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.
You may also be interested in...
NICE is not recommending Dupixent for severe asthma just yet but Sanofi remains confident of hitting its sales target of €10bn a year.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.